D
Capricor Therapeutics, Inc. CAPR
$6.62 -$0.10-1.49% NASDAQ
Recommendation
Prev Close
$6.72
Volume
749,812
Avg Vol (90D)
2,141,288
Market Cap
$307.22M
Dividend & Yield
--
52-Week Range
$5.68 - $23.40
P/E (TTM)
--
EPS (TTM)
-$1.64
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Capricor Therapeutics management to meet with Piper Sandler
10/14/2025 - The Fly
Capricor Therapeutics (CAPR, $6.72) entered Downtrend as Momentum indicator drops below 0 level on Oct 13, 2025
10/14/2025 - Tickeron - Technical Analysis
The Implied Analyst 12-Month Target For IBRN
10/13/2025 - ETF Channel
Capricor Therapeutics (CAPR): Assessing Valuation After FDA Setback and Class Action Complaint
10/10/2025 - Simply Wall St
Weiss Ratings Reaffirms "Sell (D-)" Rating for Capricor Therapeutics (NASDAQ:CAPR)
10/10/2025 - MarketBeat
Is FDA Embrace of HOPE-3 Data Shaping the Investment Thesis for Capricor Therapeutics (CAPR)?
10/9/2025 - Simply Wall St
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/8/2025 - Globe Newswire
Capricor Therapeutics management to meet with Piper Sandler
10/7/2025 - TipRanks Financial Blog
Capricor Therapeutics management to meet with Piper Sandler
10/7/2025 - The Fly
Capricor Therapeutics (CAPR, $7.36) RSI Indicator left the overbought zone on October 03, 2025
10/4/2025 - Tickeron - Stocks
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages ...
10/3/2025 - GuruFocus
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
10/3/2025 - Globe Newswire
Capricor Therapeutics (CAPR, $7.97) RSI Indicator left the overbought zone on October 02, 2025
10/3/2025 - Tickeron - Stocks
Capricor Therapeutics (CAPR, $7.82) price may drop as it broke higher Bollinger Band on Oct 01, 2025
10/2/2025 - Tickeron - Stocks
Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway
9/29/2025 - Seeking Alpha - Long Ideas
Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway
9/29/2025 - SeekingAlpha
Capricor Therapeutics (CAPR, $7.09) price may drop as it broke higher Bollinger Band on Sep 26, 2025
9/27/2025 - Tickeron - Stocks
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Consensus Recommendation of "Buy" by Brokerages
9/27/2025 - MarketBeat
Capricor Therapeutics (CAPR, $6.52) entered Uptrend as Momentum indicator ascends above 0 level on Sep 25, 2025
9/26/2025 - Tickeron - Technical Analysis
Noteworthy Thursday Option Activity: TRTX, U, CAPR
9/25/2025 - Stock Options Channel
HC Wainwright Reiterates "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR)
9/25/2025 - MarketBeat
Why Capricor Therapeutics Stock Is Surging Today
9/25/2025 - Benzinga
Capricor Therapeutics, Inc. (CAPR) DMD Program Update Call (Transcript)
9/25/2025 - Seeking Alpha: Transcripts
Capricor Therapeutics (CAPR) Advances in Duchenne Muscular Dystrophy Study
9/25/2025 - GuruFocus
Capricor Therapeutics (CAPR) Gains on FDA Regulatory Flexibility for Deramiocel
9/25/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$13.39M
EBITDA (TTM)
-$71.78M
EBIT (TTM)
-$73.41M
Net Income (TTM)
-$69.98M
Balance Sheet
Total Assets (Q)
$133.57M
Total Debt (Q)
$1.04M
Total Liabilities (Q)
$28.59M
Book Value Per Share (Q)
$2.30
Cash Flow
Cash from Operations (TTM)
-$52.99M
Cash from Investing (TTM)
-$82.94M
Cash from Financing (TTM)
$148.48M
Net Change in Cash (TTM)
$12.55M
Filings
Filing Date
Monday, August 11, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
0.86
7-Day Total Return
-10.05%
30-Day Total Return
4.58%
60-Day Total Return
5.58%
90-Day Total Return
-49.77%
Year to Date Total Return
-55.75%
1-Year Total Return
-66.19%
2-Year Total Return
132.69%
3-Year Total Return
13.55%
5-Year Total Return
36.49%
52-week Low
Sep 04, 2025 - $5.68
52-week High
Oct 15, 2024 - $23.40
Valuation
Market Cap
$307.22M - Small Cap
Enterprise Value
$185.46M
Price/Sales (TTM)
22.94
Price/Book (Q)
2.93
Dividends and Shares
Shares Outstanding
45.71
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.capricor.com
Phone Number
858 727 1755
Address
10865 Road to the Cure
San Diego, CA 92121
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy... more
NASDAQ 10/14/2025 3:49PM Eastern Quotes delayed